Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals

Psychopharmacology

Volumn 214, Issue 4, 2011, Pages 855-862

  Rowlett, James K ^e   Kehne, John H ^a,b   Sprenger, Ken J ^a,d   Maynard, George D ^a,c  

^a NEUROGEN CORPORATION   (United States)

^b Translational Neuropharmacology Consulting LCC   (United States)

^c Axerion Therapeutics   (United States)

^d PFIZER INC   (United States)

^e NONE

Author keywords

Anxiolytic; Benzodiazepine; GABA receptor; Primate

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; TRIAZOLAM; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONFLICT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SELECTIVITY; DRUG TOLERANCE; ELECTRIC SHOCK; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RESPONSE TIME; RHESUS MONKEY; SEDATION; STIMULUS RESPONSE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; CONDITIONING, OPERANT; CONFLICT (PSYCHOLOGY); ELECTROSHOCK; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; PROTEIN BINDING; PYRIDINES; RECEPTORS, GABA-A; REINFORCEMENT (PSYCHOLOGY); TIME FACTORS;

EID: 79953648711     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2093-3     Document Type: Article

References (39)

1. Auta J, Romeo E, Kozikowski A, Ma D, Costa E, Guidotti A (1993) Participation of mitochondrial diazepam binding inhibitor receptors in the anti-conflict, antineophobic and anticonvulsant action of 2-aryl-3- indoleacetamide and imidazopyridine derivatives. J Pharmacol Exp Ther 265:649-656 (Pubitemid 23315570)
2. 2 models of experimental human anxiety. J Psychopharmacol 23:117-122
3. Barbanoj MJ, Urbano G, Antonijoan R, Ballester MR, Valle M (2007) Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. Neuropsychobiology 55:203-212 (Pubitemid 47525241)
4. Davis MF, Onaivi ES, Chen SW, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49:47-56 (Pubitemid 24297256)
5. Davis M, Walker DL, Miles L, Grillon C (2010) Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacology 35:105-135
6. de Haas S, Schoemaker R, van Gerven J, Hoever P, Cohen A, Dingemanse J (2009) Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 24:1619-1629
7. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G (1986) Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658 (Pubitemid 16092830)
8. Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, Goodacre S, Lincoln RJ, Cook SM, Conley R, Hallett D, Humphries AC, Thompson SA, Wafford KA, Street LJ, Castro JL, Whiting PJ, Rosahl TW, Atack JR, McKernan RM, Dawson GR, Reynolds DS (2005) Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25:10682-10688 (Pubitemid 41681916)
9. Dixon CI, Morris HV, Breen G, Desrivieres S, Jugurnauth S, Steiner RC, Vallada H, Guindalini C, Laranjeira R, Messas G, Rosahl TW, Atack JR, Peden DR, Belelli D, Lambert JJ, King SL, Schumann G, Stephens DN (2009) Cocaine effects on mouse incentive-learning and human addiction are linked to alpha2 subunit-containing GABAA receptors. Proc Natl Acad Sci USA 107:2289-2294
10. Gerak LR, McMahon LR, France CP (2008) Acute cross-tolerance to midazolam, and not pentobarbital and pregnanolone, after a single dose of chlordiazepoxide in monkeys discriminating midazolam. Behav Pharmacol 19:796-804
11. Griebel G, Sanger DJ, Perrault G (1996) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective benzodiazepine receptor ligands. Psychopharmacology 124:245-254
12. Guisti P, Guidetti G, Costa E, Guidotti A (1991) The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action. J Pharmacol Exp Ther 257:1062-1068
13. Hutchinson MA, Smith PF, Darlington CL (1996) The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog Neurobiol 49:73-97 (Pubitemid 26199220)
14. Ihmsen H, Albrecht S, Hering W, Schüttler J, Schwilden H (2004) Modeling acute tolerance to the EEG effect of two benzodiazepines. Br J Clin Pharmacol 57:153-161 (Pubitemid 38223527)
15. Ingum J, Bjorklund R, Volden R, Morland J (1994) Development of acute tolerance after oral doses of diazepam and flunitrazepam. Psychopharmacology 113:304-310 (Pubitemid 24150472)
16. A receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4- (pyrrolidin-1-yl-carbonyl)- 2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. J Pharmacol Exp Ther 313:1118-1125
17. Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann H, Möhler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131-134
18. Margules DL, Stein L (1968) Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam. Psychopharmacologia 13:74-80
19. Massotti M, Schlichting JL, Antonacci MD, Giusti P, Memo M, Costa E, Guidotti A (1991) gamma-Aminobutyric acid A receptor heterogeneity in rat central nervous system: studies with clonazepam and other benzodiazepine ligands. J Pharmacol Ex Ther 256:1154-1160
20. A receptor alpha1 subtype. Nat Neurosci 3:587-592
21. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244
22. Mitchell CP, Ost ML, Flaherty CF (2004) Evidence for zolpidem-induced hyperphagia, but not anxiolysis, in a successive negative contrast paradigm. Pharmacol Biochem Beh 79:523-531 (Pubitemid 39576170)
23. Morlock RJ, Tan M, Mitchell DY (2006) Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey data, 1997-2002. Clin Ther 28:1044-1053 (Pubitemid 44380322)
24. Nutt DJ (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 10:49-56
25. Paronis CA, Cox ED, Cook JM, Bergman J (2001) Different types of GABAA receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys. Psychopharmacology 156:461-468 (Pubitemid 32695856)
26. Patat A, Trocherie S, Thebault JJ, Rosenzweig P, Dubruc C, Bianchetti G, Court LA, Morselli PL (1994) EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology 114:138-146 (Pubitemid 24150531)
27. Platt DM, Carey GJ, Spealman RD (2005) Intravenous self-administration techniques in monkeys. In: Enna S, Williams M, Ferkany J, Kenakin T, Porsolt R, Sullivam J (eds) Current protocols in neuroscience. Wiley, New York, Unit 9.21
28. 1-preferring antagonist β-CCt in squirrel monkeys. Psychopharmacology 164:151-159
29. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915-920 (Pubitemid 40282765)
30. A receptors. Psychopharmacology 184:201-211
31. Rudolph U, Crestani F, Möhler H (2001) GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188-194 (Pubitemid 32244305)
32. Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(Suppl 1):9-15, discussion 41, 43-45
33. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355-372 (Pubitemid 24258708)
34. Sanger DJ, Zivkovic B (1988) Further behavioural evidence for the selective sedative action of zolpidem. Neuropharmacology 27:1125-1130 (Pubitemid 18261175)
35. Smith RB, Kroboth PD, Varner PD (1987) Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 27:971-979
36. Uhde TW, Cortese BM, Vedeniapin A (2009) Anxiety and sleep problems: emerging concepts and theoretical treatment implications. Curr Psychiatr Rep 11:269-276
37. Vanover KE, Robledo S, Huber M, Carter RB (1999) Pharmacological evaluation of a modified conflict procedure: punished drinking in non-water deprived rats. Psychopharmacology 145:333-341 (Pubitemid 29393484)
38. Verster JC, Volkerts ER (2004) Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 10:45-76 (Pubitemid 38381174)
39. Aergic drugs using temperature and locomotor responses to acute stress. Psychopharmacology 204:299-311